Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Can-Fite BioPharma Ltd (Can-Fite) is a clinical-stage drug development company that strives to develop small-molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products include Piclidenoson (CF101), which treats psoriasis, lowe Syndrome and dog osteoarthritis; Namodenoson (CF102) treats liver cancer, pancreatic cancer and metabolically-associated steatohepatitis; and CF602 targets erectile dysfunction. The company works in collaboration with pharmaceutical and biotechnology companies to develop its product portfolio. Can-Fite is headquartered in Petah Tikva, Israel.
Headquarters
Israel
Address
P.O. Box 7537, 10 Bareket Street, Kiryat Matalon, Petah Tikva, 49170
Website
www.canfite.com
Telephone
972 3 9241114
No of Employees
5
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CANF (TLV)
Revenue (2024)
$405,000
-39.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-24.7%
(2024 vs 2023)
Market Cap*
$9.8M
Net Profit Margin (2024)
XYZ
-107.6%
(2024 vs 2023)
* As of and is in US$
Can-Fite BioPharma Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| CF602: Erectile Dysfunction |
| Piclidenoson (CF101): Psoriasis, Lowe sSndrome, Dog Osteoarthritis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Can-Fite BioPharma Ltd | Pfizer Inc | Amgen Inc | BioLineRx Ltd | Chemomab Therapeutics Ltd |
|---|---|---|---|---|---|
| Headquarters | Israel | United States of America | United States of America | Israel | Israel |
| City | Petah Tikva | New York City | Thousand Oaks | Modi'in-Maccabim-Re'ut | Tel Aviv |
| State/Province | Petah Tikva | New York | California | - | Tel Aviv |
| No. of Employees | 5 | 75,000 | 31,500 | 24 | 12 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Pnina Fishman, Ph.D. | Chairman; Chief Scientific Officer | Executive Board | - | 75 |
| Motti Farbstein | Chief Executive Officer; Chief Operating and Financial Officer | Senior Management | - | 61 |
| Sari Fishman | Vice President - Business Development | Senior Management | - | - |
| William D. Kerns | Vice President - Drug Development | Senior Management | - | - |
| Michael Silverman | Director - Medical | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer